ES2100861T3 - Composiciones farmaceuticas para la inhibicion de la reaccion de maillard. - Google Patents

Composiciones farmaceuticas para la inhibicion de la reaccion de maillard.

Info

Publication number
ES2100861T3
ES2100861T3 ES90122096T ES90122096T ES2100861T3 ES 2100861 T3 ES2100861 T3 ES 2100861T3 ES 90122096 T ES90122096 T ES 90122096T ES 90122096 T ES90122096 T ES 90122096T ES 2100861 T3 ES2100861 T3 ES 2100861T3
Authority
ES
Spain
Prior art keywords
chem
hydrogen
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90122096T
Other languages
English (en)
Inventor
Jun Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2100861T3 publication Critical patent/ES2100861T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN COMPOSICIONES FARMACEUTICAS QUE ESTAN COMPUESTAS, EN MEZCLA CON UN CATALIZADOR, DE UN COMPUESTO DE; A) LA FORMULA (I) O UNA SAL DE ESTE ACEPTABLE FARMACEUTICAMENTE: EN LA QUE R SUB 1 Y R SUB 2 SON CADA UNO HIDROGENO, METILO, TRIFLUOROMETILO, CARBOXI, METOXICARBONIL O ETOXICARBONIL, Y R SUB 3 ES HIDROGENO O HIDROXI; B) LA FORMULA (I) O UNA SAL DE ESTE FARMACEUTICAMENTE ACEPTABLE: EN LA QUE R SUB 1, R SUB 2 Y R SUB 3 SON COMO SE HA DEFINIDO; C) LA FORMULA (III) O UNA SAL DE ESTE FARMACEUTICAMENTE ACEPTABLE: EN LA QUE R SUB 4 Y R SUB 5 SON CADA UNO HIDROGENO O FORMAN, CON LA INCORPORACION DE ATOMOS DE CARBONO C SUB 1 Y C SUB 2, UN ANILLO DE [2.1-B] PIRIDINA CONDENSADA SUSTITUIDA OPCIONALMENTE CON UN GRUPO HIDROXILO O CARBOXILO, Y R SUB 6 ES HIDROGENO O HIDROXI; O (D) LA FORMULA (IV) O UNA SAL DE ESTE FARMACEUTICAMENTE ACEPTABLE: EN LA QUE R SUB 4, R SUB 5 Y R SUB 6 SON COMO SE HA DEFINIDO. LAS COMPOSICIONES SE UTILIZAN PARA INHIBIR LA REACCION DE MAILLARD EN EL CUERPO HUMANO, LA REACCION QUE PUEDE SER CAUSANTE DEL DESARROLLO DE COMPLICACIONES DIABETICAS Y MOLESTIAS ASOCIADAS A LA EDAD. TAMBIEN SE PRESENTAN LOS METODOS DE TRATAMIENTOS Y LA PROFILAXIS DE ESTAS COMPLICACIONES Y DESORDENES.
ES90122096T 1989-11-20 1990-11-19 Composiciones farmaceuticas para la inhibicion de la reaccion de maillard. Expired - Lifetime ES2100861T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1301413A JPH03161441A (ja) 1989-11-20 1989-11-20 メイラード反応阻害剤

Publications (1)

Publication Number Publication Date
ES2100861T3 true ES2100861T3 (es) 1997-07-01

Family

ID=17896581

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90122096T Expired - Lifetime ES2100861T3 (es) 1989-11-20 1990-11-19 Composiciones farmaceuticas para la inhibicion de la reaccion de maillard.

Country Status (7)

Country Link
EP (1) EP0433679B1 (es)
JP (1) JPH03161441A (es)
KR (1) KR910009665A (es)
AT (1) ATE152352T1 (es)
CA (1) CA2029421A1 (es)
DE (1) DE69030616T2 (es)
ES (1) ES2100861T3 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP3988838B2 (ja) * 1996-05-29 2007-10-10 日本製粉株式会社 化粧料
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO2000010606A1 (fr) 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux
FR2797443B1 (fr) * 1999-08-13 2003-10-31 Lafon Labor Procede de prepartion de quinoleine-5,8-diones
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
FR2864535B1 (fr) * 2003-12-24 2006-12-22 Merck Sante Sas Derives acides de quinoline et leurs applications en therapeutique
JP4739705B2 (ja) * 2004-07-21 2011-08-03 ロート製薬株式会社 内服用組成物
JP4894902B2 (ja) * 2009-09-25 2012-03-14 パナソニック電工株式会社 除毛機
JP4971403B2 (ja) * 2009-09-25 2012-07-11 パナソニック株式会社 除毛機
CN108558906A (zh) * 2018-05-21 2018-09-21 日照市普达医药科技有限公司 一种治疗白内障药物苯并吩噁嗪类化合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359455A (en) * 1979-10-30 1982-11-16 Sunstar Hamigaki Kabushiki Kaisha Diagnostic test composition for dental caries activity
IN164557B (es) * 1986-08-27 1989-04-08 Hoechst Ag
JPH01211595A (ja) * 1988-02-18 1989-08-24 Kikkoman Corp 新規Ｎ−アセチル−β−Ｄ−グルコサミン誘導体、その製法及びＮ−アセチル−β−Ｄ−グルコサミニダーゼ活性測定用試薬への利用
US5112739A (en) * 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system

Also Published As

Publication number Publication date
DE69030616T2 (de) 1997-12-11
ATE152352T1 (de) 1997-05-15
DE69030616D1 (de) 1997-06-05
CA2029421A1 (en) 1991-05-21
EP0433679A2 (en) 1991-06-26
KR910009665A (ko) 1991-06-28
JPH03161441A (ja) 1991-07-11
EP0433679B1 (en) 1997-05-02
EP0433679A3 (en) 1992-03-04

Similar Documents

Publication Publication Date Title
ES2100861T3 (es) Composiciones farmaceuticas para la inhibicion de la reaccion de maillard.
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
IE861820L (en) 2-hydroxy-2-phenylethylaminotetralines
IE890500L (en) 3-alkenyl-1-azabicyclo£3.2.0|hept-2-ene-2-carboxylic acid compounds
GR3018387T3 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
ATE157980T1 (de) Tetrahydropyrrolo(1,2-a>pyrazin-4-spiro-3'- pyrrolidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
DK0514357T3 (da) Anvendelse af estere af acyl-L-carnitiner med gamma-hydroxysmørsyre til fremstilling af farmaceutiske præparater til behandling af hepatopatier
GB8608893D0 (en) D-nor-7-ergoline derivatives
AU2013888A (en) Uricosuric composition
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
SG4595G (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
ATE97902T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 433679

Country of ref document: ES